Trevi Therapeutics (TRVI) Institutional Ownership
13F filers reported holding 58.2% of Trevi Therapeutics (TRVI) shares as of Sep 30, 2026, across 153 filers.
- Held by 13F filers
- 58.2%
- Sep 30, 2026
- 13F filers
- 153
- quarter ended Sep 30, 2026
- 13F value
- $1.2B
- 82.9M shares
- Quarter's fund flow
- Mild accumulation
- 20 new · 15 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Mathers Edward T | director | Acquired · Grant / award | 35,000Nonstatutory Stock Option (right to buy) | — | ↗ |
| Jun 3, 2026 | Meeker David P | director | Acquired · Grant / award | 35,000Nonstatutory Stock Option (right to buy) | — | ↗ |
| Jun 3, 2026 | VANLENT ANNE | director | Acquired · Grant / award | 35,000Nonstatutory Stock Option (right to buy) | — | ↗ |
| Jun 3, 2026 | Colangelo Dominick | director | Acquired · Grant / award | 35,000Nonstatutory Stock Option (right to buy) | — | ↗ |
| Jun 3, 2026 | Heffernan Michael Thomas | director | Acquired · Grant / award | 35,000Nonstatutory Stock Option (right to buy) | — | ↗ |
| Feb 19, 2026 | Cassella James V | Chief Development Officer | Acquired · Grant / award | 215,000Stock Option (right to buy) | — | ↗ |
| Feb 19, 2026 | Galletta Christopher | See Remarks | Acquired · Grant / award | 35,000Stock Option (right to buy) | — | ↗ |
| Feb 19, 2026 | SCIASCIA THOMAS | Chief Scientific Officer | Acquired · Grant / award | 85,000Stock Option (right to buy) | — | ↗ |
| Feb 19, 2026 | GOOD JENNIFER L | President & CEO | Acquired · Grant / award | 675,000Stock Option (right to buy) | — | ↗ |
| Feb 19, 2026 | Simon Farrell | Chief Commercial Officer | Acquired · Grant / award | 160,000Stock Option (right to buy) | — | ↗ |
| Jan 8, 2026 | HASTINGS DAVID C | Chief Financial Officer | Acquired · Grant / award | 375,000Stock Option (right to buy) | — | ↗ |
| Dec 2, 2025 | Galletta Christopher | See Remarks | Acquired · Option exercise | 4,225 | $0.51 | ↗ |
| Dec 2, 2025 | Galletta Christopher | See Remarks | Disposed · Option exercise | 4,225Stock Option (right to buy) | — | ↗ |
| Jun 11, 2025 | Mathers Edward T | director | Acquired · Grant / award | 45,000Nonstatutory Stock Option (right to buy) | — | ↗ |
| Jun 11, 2025 | Colangelo Dominick | director | Acquired · Grant / award | 45,000Nonstatutory Stock Option (right to buy) | — | ↗ |
| Jun 11, 2025 | Heffernan Michael Thomas | director | Acquired · Grant / award | 45,000Nonstatutory Stock Option (right to buy) | — | ↗ |
| Jun 11, 2025 | VANLENT ANNE | director | Acquired · Grant / award | 45,000Nonstatutory Stock Option (right to buy) | — | ↗ |
| Jun 11, 2025 | Meeker David P | director | Acquired · Grant / award | 45,000Nonstatutory Stock Option (right to buy) | — | ↗ |
| May 31, 2025 | Galletta Christopher | See Remarks | Acquired · Grant / award | 8,550Performance Stock Option (right to buy) | — | ↗ |
| May 31, 2025 | SCIASCIA THOMAS | Chief Scientific Officer | Acquired · Grant / award | 60,000Performance Stock Option (right to buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Trevi Therapeutics do institutions hold?
13F filers reported holding 58.2% of Trevi Therapeutics' shares as of Sep 30, 2026, across 153 filers.
How many 13F filers hold Trevi Therapeutics?
Trevi Therapeutics was held by 153 13F filers as of Sep 30, 2026.
Not investment advice.

